All In Biotech

Drug Trial Radar · NCT06667999

The Intensive Care Platform Trial

The Intensive Care Platform Trial (INCEPT)

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Jun 26, 2025

Primary completion

Dec 2035

Study completion Dec 2035

Sponsor

Lead sponsor
Anders PernerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Copenhagen University Hospital, Rigshospitalet; Bispebjerg Hospital; Herlev Hospital; Hillerod Hospital, Denmark; Kolding Sygehus; Zealand University Hospital; Slagelse Hospital; Viborg Regional Hospital; Aalborg University Hospital; Aarhus University Hospital; Gødstrup Hospital; Copenhagen University Hospital, Hvidovre; Odense University Hospital; Randers Regional Hospital; University of Copenhagen; North Denmark Region; Region Capital Denmark; Region Zealand; University Medical Center Groningen; Steno Diabetes Center Copenhagen; Karolinska Institutet; Oslo University Hospital; University Hospital, Basel, Switzerland; Tampere University; Collaboration of Research in Intensive Care; Danish Intensive Care Database; The National University Hospital of Iceland
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Among critically ill patients, many die, and many of the survivors and their family members struggle for years with reduced quality of life. Critically ill patients are treated in intensive care units (ICUs). Here, they receive life support, e.g., mechanical ventilation and advanced support of the circulation (heart and blood vessels) and kidneys. In addition, ICU patients receive many other treatments. It is, however, uncertain if all the treatments provide value for the patients. The desirable effects of many treatments are uncertain, and some may be wasteful or even harmful. Clinical trials are necessary to validly assess the desirable and undesirable effects of different treatments. However, conventional clinical trials have limitations: * They typically only assess a single question related to a single comparison of treatments at a time. * They are often not very flexible, including with regards to the number of participants needed, and this increases the risk that a trial will end up as inconclusive. * There is no or limited re-use or sharing of infrastructure across trials, leading to duplicate work and resource use. * Trial participants do usually not benefit from the obtained knowledge before the trial concludes. * Involvement of patients, family members, and other stakeholders is typically limited, which may decrease the relevance of the questions addressed. With the Intensive Care Platform Trial (INCEPT), we aim to tackle these challenges by establishing a flexible platform trial that continuously learns from the obtained results. The platform trial may run forever with simultaneous and continuous assessment of many treatments. INCEPT will continuously learn from the accrued data and use these to improve the treatment of both participating and future patients. With INCEPT, we are also building a framework for thorough and extensive involvement of key stakeholders, including patients and family members. INCEPT will improve the way clinical trials are done and increase the probabilities that treatments are improved. This will: * Directly improve outcomes for ICU patients. * Relieve a strained healthcare system by discarding inefficient or harmful treatments. * Ensure that new treatments are beneficial or cost-effective before implementation. * Lower the costs and burdens of assessing more treatments in the critically ill.

Conditions

  • Intensive Care Patients
  • Intensive Care Unit Patients
  • Critical Illness

Interventions

  • AlbuminDrug

    Albumin should be used for the following indications: 1. During circulatory failure in addition to crystalloids (resuscitation). 2. For substitution in case of: suspected or overt albumin loss OR P-albumin levels below or equal to 25 g/L. Decisions around timing, volume, and concentration of albumin, and its use for other indications, are at the clinician's discretion. P-albumin should be measured according to local practice.

  • No albumin useOther

    Albumin should not be used. In case of the following special circumstances, albumin may be considered: 1. Large ascites drainage (i.e., equal to or more than 1 L tapped) 2. Spontaneous bacterial peritonitis 3. Hepatorenal syndrome.

  • LMWH in weight-adjusted doseDrug

    Patients with indication for thromboprophylaxis receive low-molecular-weight heparin (LMWH) in a weight-adjusted dose during their ICU stay. The treating clinician may decide to adjust or withhold one or more doses in case of acute and/or chronic kidney injury, renal replacement therapy, thrombocytopenia, invasive procedures, use of thrombolysis, and active (major) bleeding.

  • LMWH in fixed low doseDrug

    Patients with indication for thromboprophylaxis receive low-molecular-weight heparin (LMWH) in a fixed low dose during their ICU stay. The treating clinician may decide to adjust or withhold one or more doses in case of acute and/or chronic kidney injury, renal replacement therapy, thrombocytopenia, invasive procedures, use of thrombolysis, and active (major) bleeding.

  • LMWH in fixed intermediate doseDrug

    Patients with indication for thromboprophylaxis receive low-molecular-weight heparin (LMWH) in a fixed intermediate dose during their ICU stay. The treating clinician may decide to adjust or withhold one or more doses in case of acute and/or chronic kidney injury, renal replacement therapy, thrombocytopenia, invasive procedures, use of thrombolysis, and active (major) bleeding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. One of the INCEPT core outcomes (varying between domains)Time frame: From randomisation to 30-180 days after randomisation.
  2. Days alive without life support at day 30 (Albumin domain)Time frame: From randomisation to 30 days after randomisation.
  3. Days alive and out of hospital at day 30 (Thromboprophylaxis domain)Time frame: From randomisation to 30 days after randomisation.

Locations

40 sites in 7 countries. Site status is shown where the registry gives one.

  • Medical University Of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine

    Vienna, Austria · Not yet recruiting

  • Anaesthesia, Hospital Sønderjylland

    Aabenraa, Denmark · Not yet recruiting

  • Department of Anaesthesia and Intensive Care, Aalborg University Hospital

    Aalborg, Denmark · Recruiting

  • Department of Intensive Care Nord , Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Department of Intensive Care Øst, Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Department of Cardiothoracic Anaesthesia and Intensive care, Copenhagen Universisty Hospital - Rigshospitalet

    Copenhagen, Denmark · Not yet recruiting

  • Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Neuroanaesthesiology, Copenhagen University Hospital - Rigshospitalet

    Copenhagen, Denmark · Not yet recruiting

  • Department of anesthesiology and intensive care, Bispebjerg-Frederiksberg Hospital

    Copenhagen, Denmark · Recruiting

  • Esbjerg Hospital

    Esbjerg, Denmark · Not yet recruiting

  • Department of Anesthesiology and Intensive Care, Copenhagen University Hospital Herlev

    Herlev, Denmark · Not yet recruiting

  • Department of Anaesthesiology and Intensive Care, Gødstrup Hospital

    Herning, Denmark · Recruiting

  • Department of Anaesthesia and Intensive Care Medicine, Copenhagen University Hospital - North Zealand

    Hillerød, Denmark · Recruiting

  • Regional Hospital Horsens, Department of Anaesthesia, Surgery, and Intensive Care

    Horsens, Denmark · Not yet recruiting

  • Anaesthesiology and Intensive Care, Amager and Hvidovre Hospital

    Hvidovre, Denmark · Recruiting

  • Department of Anesthesia, Zealand University Hospital

    Køge, Denmark · Recruiting

  • Department of Anesthesia and intensive care medicine, Kolding Hospital

    Kolding, Denmark · Recruiting

  • Anesthesiology (ICU), Zealand University Hospital, Nykøbing Falster

    Nykøbing Falster, Denmark · Not yet recruiting

  • Department of Anesthesiology and Intensive Care, Odense University Hospital

    Odense, Denmark · Recruiting

  • Operation og Intensiv, Regional Hospital Randers

    Randers, Denmark · Recruiting

  • Intensive care, Slagelse Hospital

    Slagelse, Denmark · Recruiting

  • Department. of Anesthesiology and Intensive Care Medicine

    Svendborg, Denmark · Recruiting

  • Department of Anaesthesiology and Intensive Care, Regional Hospital Viborg

    Viborg, Denmark · Recruiting

  • East Tallinn Central Hospital, Centre of Anaesthesiology and Intensive Care

    Tallinn, Estonia · Not yet recruiting

  • North Estonia Medical Centre Foundation, Intensive Care Centre

    Tallinn, Estonia · Not yet recruiting

  • Tartu University Hospital, Anesthesiology and Intensive Care Clinic

    Tartu, Estonia · Not yet recruiting

  • Perioperative and Intensive Care,, Helsinki University Hospital

    Helsinki, Finland · Not yet recruiting

  • Department of Anesthesiology and Intensive Care, Hospital Nova of Central Finland

    Jyväskylä, Finland · Not yet recruiting

  • Department of Anaesthesiology and Intensive Care, Kuopio University Hospital

    Kuopio, Finland · Not yet recruiting

  • Anaesthesiology and Intensive Care Medicine, Tampere University Hospital

    Tampere, Finland · Not yet recruiting

  • Department of Anaesthesiology and Critical Care Medicine, Landspitali - The National University Hospital of Iceland

    Reykjavik, Iceland · Recruiting

  • Critical Care, University Medical Center Groningen

    Groningen, Netherlands · Recruiting

  • Intensive Care, Martini Hospital Groningen

    Groningen, Netherlands · Not yet recruiting

  • tensive Care Medicine, Maastricht UMC+

    Maastricht, Netherlands · Not yet recruiting

  • Anesthesiology and Intensive Care, Antonius Ziekenhuis Sneek

    Sneek, Netherlands · Not yet recruiting

  • Intensive and Perioperative Care, Skane University Hospital

    Malmö, Sweden · Not yet recruiting

  • Södersjukhuset Sachsska Barnsjukhuset, Department of Anesthesia and Intensive care

    Stockholm, Sweden · Not yet recruiting

  • Department of Anaesthesia and Intensive Care, Danderyd Hospital

    Stockholm, Sweden · Not yet recruiting

  • Region Vaesternorrland, Department of Anesthesia and Intensive Care

    Sundsvall, Sweden · Not yet recruiting

  • Perioperativ Medicin och Intensivvård, Karolinska Universitetssjukhuset

    Stockholm, Solna, Sweden · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.